Novavax (NVAX) On Thursday, he reported a big decline in sales in the fourth quarter on Thursday – and said he no longer wanted to be known simply as a vaccine manufacturer.
COVID-19 Vaccine based in Maryland stated during the earnings report that it would move from the development of products to a partnership with larger pharmaceutical companies and licensing their drug technology.
Novavax reported in the fourth quarter of $ 88 million income compared to $ 291 million in the previous year and $ 682 million for $ 2024, compared to $ 984 million in the previous year. A strip decrease reflected the forfeiture of the sale of the vaccine against COVID-19-similar to other vaccine manufacturers. Sales data also reflected $ 200 million from the sale of production facilities in the Czech Republic Novo Nordisk (Non -governmental organization).
Wall Street was expecting $ 84 million for a quarter of $ 84 million and a $ 0.75 loss per quarter. The company showed a loss of $ 0.51 for quarter, estimates defeating and losing $ 1.23 per share for the whole year, and also defeated estimates. The company missed the annual income estimates where Wall Street expected $ 684 million.
Novavax shares were flat on Thursday.
Read more: Is health insurance deductible? Here's what you can say.
Matrix-M Adjuvans, which helped to improve the effectiveness of the vaccine against COVID-19, Nuvaxovid, helped to seal two partnerships last year and other companies show interest, said John Jacobs Yahoo Finance.
The shift of Biotech to a drug platform society could reduce its exposition to the head of Trump's administration – namely negative impacts on the vaccine manufacturer from the newly confirmed Minister of Health and Human Services Robert F. Kennedy Jr.
Just this week, the FDA Committee meeting If you want to choose which flu tribe every year was canceled. And the federal government Reassesses its financing a candidate for a bird's flu vaccine from modern (MRNA). On the day of appointment of RFK, All vaccine manufacturersIncluding Novavax, they saw their supplies to slip.
Jacobs, however was the moon stopped FDA at the end of last year.
Novavax had to face the sudden rise and fall of its wealth bound to pandemics, as well as other Covid vaccine companies such as Modern and Pfizer (PFE).
The fight of Novavax was deepened by its inability to gain market share outside other Covid players after the FDA permission came across several times the process of experiments and production. To date, the company has not yet received a complete vaccine permit, but the FDA is expected to decide by April this year.
